A Rebuttal - Oral Contraceptives and Venous Thrombosis: Reply

• References

• 1 Greaves M, Preston FE. Oral contraceptives and venous thrombosis. Thromb Haemost 2001; 85: 932-4.
• 2 Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives (OCs). Thromb Haemost 2000; 84: 1-3.
• 3 Kluft C. Disorders of the hemostatic system and the risk of the development of thrombotic and cardiovascular diseases: limitations of laboratory diagnosis. Am J Obstet Gynecol 1990; 163: 305-12.
• 4 Gaspard U, Jespersen J, Kluft C, Mattson L-A, Samsioe G, Skouby SO. Consensus development meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990; 162: 1335-7.
• 5 Writing Committee.. Consensus Statement of the consensus development meeting 1995: combined oral contraceptives and cardiovascular disease. Gynecol Endocrinol 1996; 10: 1-5.
• 6 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
• 7 Kluft C. Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies. Curr Med Chem 2000; 7: 585-91.
• 8 Kluft C. Pro-inflammatory effects of oestrogens. Fibrinolysis Proteolysis 1999; 13: 217-9.
• 9 Rosing J, Tans G, Nicolaes GAF, Thomassen MCLGD, van Oerie R, van der Ploeg PMEN, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
• 10 Kluft C, de Maat MP, Heinemann LA, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagula tion. Lancet 1999; 354: 832-3.
• 11 Kluft C, Meijer P, Gram J, Jespersen J. Acquired activated protein-C resistance. Lancet 1999; 353: 1882.
• 12 Curvers J, Thomassen MCLGD, Nicolaes GAF, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
• 13 De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
• 14 Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VlII-clotting activity. Thromb Haemost 1995; 74: 1198-9.
• 15 Heinemann LAJ, Assman A, Spannagl M, Schramm W, Dick A, Kluft C, de Maat MPM. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 1998; 58: 321-2.
• 16 Tans G, Rosendaal FR, Curvers J, Thomassen MCLGD, Bertina RM, Rosing J. APC resistance determined with the endogenous thrombin potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999; (supplement) 202-3 (abstract 640).
• 17 GrandiMaison A, Douketis J, Bates SM, Johnston M, Naguit I, Ginsberg JS. Endogenous thrombin potential and the risk of venous thromboembolism. Blood 2000; 96: 95b (abstract 4095).
• 18 Hoibraaten E, Mowinckel M-C, de Ronde H, Bertina RM, Strandberg PM. Hormone replacement therapy (HRT) induces acquired resistance to activated protein C (APC): results from a randomized, double-blind, clinical trial. Blood 2000; 96: 816a (abstract 3528).
• 19 Zotz RB, Gerhardt A, Kluft C, Scharf RE. Activated protein C sensitivity ratio based on the emdogenous thrombin potential is not a risk factor for pregnancy-associated venous thromboembolism. Blood 2000; 96: 275a (abstract 1181).
• 20 Brandt E. Medisch onderzoek gestuurd. Trouw (daily newspaper) 2001; 59 January 30 1-13.